XOMA Royalty (XOMA) Stock Price, News & Analysis

Company Overview

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $26.28 to $26.98
• 50-Day Range: $23.04 to $27.59
• 52-Week Range: $18.35 to $35.00
• Volume: 25,289 shs
• Average Volume: 35,139 shs
• Market Capitalization: $316.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $69.50
• Consensus Rating: Buy

XOMA Royalty Stock Analysis - MarketRank™

XOMA Royalty scored higher than 86% of companies evaluated by MarketBeat, and ranked 114th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

XOMA Royalty has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

XOMA Royalty has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for XOMA Royalty are expected to grow in the coming year, from ($1.41) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of XOMA Royalty is -22.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of XOMA Royalty is -22.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

XOMA Royalty has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.54% of the float of XOMA Royalty has been sold short.

Short Interest Ratio / Days to Cover

XOMA Royalty has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in XOMA Royalty has recently decreased by 11.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XOMA Royalty does not currently pay a dividend.

Dividend Growth

XOMA Royalty does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.0 / 5
• Environmental Score: -0.22

Percentage of Shares Shorted

1.54% of the float of XOMA Royalty has been sold short.

Short Interest Ratio / Days to Cover

XOMA Royalty has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in XOMA Royalty has recently decreased by 11.49%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: 0.23

News Sentiment

XOMA Royalty has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for XOMA Royalty this week, compared to 2 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, XOMA Royalty insiders have sold 6,050.42% more of their company's stock than they have bought. Specifically, they have bought $183,621.00 in company stock and sold $11,293,460.00 in company stock.

Percentage Held by Insiders

Only 9.10% of the stock of XOMA Royalty is held by insiders.

Percentage Held by Institutions

95.92% of the stock of XOMA Royalty is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XOMA Stock Analysis - Frequently Asked Questions

How have XOMA shares performed this year?

XOMA Royalty's stock was trading at $26.28 on January 1st, 2025. Since then, XOMA shares have increased by 0.6% and is now trading at $26.4340.

How were XOMA Royalty's earnings last quarter?

XOMA Royalty Corporation (NASDAQ:XOMA) posted its quarterly earnings data on Tuesday, May, 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.32. The biotechnology company had revenue of $15.91 million for the quarter, compared to analysts' expectations of $6.75 million. XOMA Royalty had a negative trailing twelve-month return on equity of 12.43% and a negative net margin of 13.04%.

How do I buy shares of XOMA Royalty?

Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of XOMA Royalty own?

Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA Royalty investors own include American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XOMA
• CIK: 791908
• Web: www.xoma.com
• Phone: (510) 204-7200
• Fax: 510-649-7571
• Employees: 10
• Year Founded: 1981

Price Target and Rating

• Average Stock Price Target: $69.50
• High Stock Price Target: $104.00
• Low Stock Price Target: $35.00
• Potential Upside/Downside: +162.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.82 million
• Net Margins: -13.04%
• Pretax Margin: -19.85%
• Return on Equity: -12.43%
• Return on Assets: -4.85%

Debt

• Debt-to-Equity Ratio: 1.18
• Current Ratio: 5.54
• Quick Ratio: 5.54

Sales & Book Value

• Annual Sales: $28.49 million
• Price / Sales: 11.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.95 per share
• Price / Book: 3.80

Miscellaneous

• Outstanding Shares: 11,970,000
• Free Float: 10,878,000
• Market Cap: $316.41 million
• Optionable: Optionable
• Beta: 0.93